

SNAI1 Antibody (N-term D24) Blocking Peptide

Synthetic peptide
Catalog # BP2054a

Specification

SNAI1 Antibody (N-term D24) Blocking Peptide - Product Information

Primary Accession [O95863](#)

SNAI1 Antibody (N-term D24) Blocking Peptide - Additional Information

Gene ID 6615

Other Names

Zinc finger protein SNAI1, Protein snail homolog 1, Protein sna, SNAI1, SNAH

Target/Specificity

The synthetic peptide sequence used to generate the antibody [AP2054a](#) was selected from the N-term region of human SNAI1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

SNAI1 Antibody (N-term D24) Blocking Peptide - Protein Information

Name SNAI1

Synonyms SNAH

SNAI1 Antibody (N-term D24) Blocking Peptide - Background

The Drosophila embryonic protein snail is a zinc finger transcriptional repressor which downregulates the expression of ectodermal genes within the mesoderm. The nuclear protein encoded by this gene is structurally similar to the Drosophila snail protein, and is also thought to be critical for mesoderm formation in the developing embryo. At least two variants of a similar processed pseudogene have been found on chromosome 2.

SNAI1 Antibody (N-term D24) Blocking Peptide - References

Imai, T., et al., Am. J. Pathol. 163(4):1437-1447 (2003). Yokoyama, K., et al., Int. J. Oncol. 22(4):891-898 (2003). Guaita, S., et al., J. Biol. Chem. 277(42):39209-39216 (2002). Blanco, M.J., et al., Oncogene 21(20):3241-3246 (2002). Okubo, T., et al., Cancer Res. 61(4):1338-1346 (2001).

Function

Involved in induction of the epithelial to mesenchymal transition (EMT), formation and maintenance of embryonic mesoderm, growth arrest, survival and cell migration. Binds to 3 E-boxes of the E-cadherin/CDH1 gene promoter and to the promoters of CLDN7 and KRT8 and, in association with histone demethylase KDM1A which it recruits to the promoters, causes a decrease in dimethylated H3K4 levels and represses transcription (PubMed:20389281, PubMed:20562920). The N-terminal SNAG domain competes with histone H3 for the same binding site on the histone demethylase complex formed by KDM1A and RCOR1, and thereby inhibits demethylation of histone H3 at 'Lys-4' (in vitro) (PubMed:20389281, PubMed:21300290, PubMed:23721412). During EMT, involved with LOXL2 in negatively regulating pericentromeric heterochromatin transcription (By similarity). SNAI1 recruits LOXL2 to pericentromeric regions to oxidize histone H3 and repress transcription which leads to release of heterochromatin component CBX5/HP1A, enabling chromatin reorganization and acquisition of mesenchymal traits (By similarity). Associates with EGR1 and SP1 to mediate tetradecanoyl phorbol acetate (TPA)-induced up-regulation of CDKN2B, possibly by binding to the CDKN2B promoter region 5'-TCACA-3. In addition, may also activate the CDKN2B promoter by itself.

Cellular Location

Nucleus. Cytoplasm. Note=Once phosphorylated (probably on Ser-107, Ser-111, Ser-115 and Ser-119) it is exported from the nucleus to the cytoplasm where subsequent phosphorylation of the destruction motif and ubiquitination involving BTRC occurs.

Tissue Location

Expressed in a variety of tissues with the highest expression in kidney. Expressed in mesenchymal and epithelial cell lines.

SNAI1 Antibody (N-term D24) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)